517 related articles for article (PubMed ID: 30143270)
1. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of universal BCG vaccination of Japanese infants.
Rahman M; Sekimoto M; Takamatsu I; Hira K; Shimbo T; Toyoshima K; Fukui T
Int J Epidemiol; 2001 Apr; 30(2):380-5. PubMed ID: 11369746
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Hersh AL; Tala-Heikkilä M; Tala E; Tosteson AN; Fordham von Reyn C
Int J Tuberc Lung Dis; 2003 Jan; 7(1):22-9. PubMed ID: 12701831
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Selective Neonatal Bacillus Calmette-Guérin Vaccination of High-risk Infants in Ireland.
Teljeur C; Moran PS; Harrington P; Butler K; Corcoran B; O'Donnell J; Usher C; O'Flanagan D; Connolly K; Ryan M
Pediatr Infect Dis J; 2018 Aug; 37(8):759-767. PubMed ID: 29432385
[TBL] [Abstract][Full Text] [Related]
5. Making wider use of the world's most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered.
Dye C
J R Soc Interface; 2013 Oct; 10(87):20130365. PubMed ID: 23904584
[TBL] [Abstract][Full Text] [Related]
6. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
8. Clinical and economic impact of a specific BCG vaccination program implemented in Prato, central Italy, involving foreign newborns on hospitalizations.
Bellini I; Nastasi A; Boccalini S
Hum Vaccin Immunother; 2016 Sep; 12(9):2383-90. PubMed ID: 27184892
[TBL] [Abstract][Full Text] [Related]
9. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
10. Risk of tuberculosis infection and tuberculous meningitis after discontinuation of Bacillus Calmette-Guerin in Beijing.
Zhang LX; Tu DH; He GX; Ma ZQ; Nagelkerke NJ; Borgdorff MW; Enarson DA; Broekmans JF
Am J Respir Crit Care Med; 2000 Oct; 162(4 Pt 1):1314-7. PubMed ID: 11029337
[TBL] [Abstract][Full Text] [Related]
11. Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
Jackson S; Kabir Z; Comiskey C
Vaccine; 2024 Mar; 42(8):2099-2105. PubMed ID: 38423810
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis.
Zelner JL; Murray MB; Becerra MC; Galea J; Lecca L; Calderon R; Yataco R; Contreras C; Zhang Z; Grenfell BT; Cohen T
Am J Respir Crit Care Med; 2014 Apr; 189(7):853-9. PubMed ID: 24592878
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of childhood tuberculosis after ceasing universal Bacillus Calmette-Guérin vaccination.
Kobayashi S; Yoshiyama T; Uchimura K; Hamaguchi Y; Kato S
Sci Rep; 2021 Aug; 11(1):15902. PubMed ID: 34354146
[TBL] [Abstract][Full Text] [Related]
14. Is Bacillus Calmette-Guerin revaccination necessary for Japanese children?
Rahman M; Sekimoto M; Hira K; Koyama H; Imanaka Y; Fukui T
Prev Med; 2002 Jul; 35(1):70-7. PubMed ID: 12079443
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
Tseng CL; Oxlade O; Menzies D; Aspler A; Schwartzman K
BMC Public Health; 2011 Jan; 11():55. PubMed ID: 21269503
[TBL] [Abstract][Full Text] [Related]
16. Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis.
Gengenbacher M; Nieuwenhuizen N; Vogelzang A; Liu H; Kaiser P; Schuerer S; Lazar D; Wagner I; Mollenkopf HJ; Kaufmann SH
mBio; 2016 May; 7(3):. PubMed ID: 27222470
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bacille Calmette-Guérin immunisation programs in Australia.
Khandaker G; Beard FH; Dey A; Coulter C; Hendry AJ; Macartney KK
Commun Dis Intell Q Rep; 2017 Mar; 41(1):E33-E48. PubMed ID: 28385137
[TBL] [Abstract][Full Text] [Related]
18. Protection against tuberculosis by Bacillus Calmette-Guérin (BCG) vaccination: A historical perspective.
Setiabudiawan TP; Reurink RK; Hill PC; Netea MG; van Crevel R; Koeken VACM
Med; 2022 Jan; 3(1):6-24. PubMed ID: 35590145
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities.
Faust L; Schreiber Y; Bocking N
BMC Public Health; 2019 Nov; 19(1):1504. PubMed ID: 31711446
[TBL] [Abstract][Full Text] [Related]
20. The BCGΔBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo.
Pedroza-Roldán C; Guapillo C; Barrios-Payán J; Mata-Espinosa D; Aceves-Sánchez Mde J; Marquina-Castillo B; Hernández-Pando R; Flores-Valdez MA
Vaccine; 2016 Sep; 34(40):4763-70. PubMed ID: 27546876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
